• Immunogenicity Assessment

    • Therapeutic In Silico Services
      • ISPRIâ„¢ Website
      • ISPRI Downselectâ„¢
      • ISPRI Quantifyâ„¢
      • ISPRI Analyzeâ„¢
      • ISPRI Evaluateâ„¢
      • ISPRI-HCPâ„¢
      • ISPRI Designâ„¢
      • PANDA® Screening
    • Vaccine In Silico Services
      • iVAXâ„¢
      • EpiCCâ„¢
      • Ancer®
      • PreVAXâ„¢
    • Lab Services
      • HLA Binding Assay
      • Naive CD4+ T Cell Assay
      • Innate Assay
    • Consulting Services
  • About Us
    • Leadership
    • Careers
  • Partner
  • Press
    • News
    • Events
    • Publications
    • Blog
  • Contact Us
Gordon Research Conference – Advancing Peptides as Tools, Materials and Therapeutics February 9-14, 2020

Gordon Research Conference – Advancing Peptides as Tools, Materials and Therapeutics February 9-14, 2020

by Annie De Groot | Jan 29, 2020 | Events

Dr. Anne De Groot will be in Ventura Beach, CA for the Gordon Research Center: Advancing Peptides as Tools, Materials and Therapeutics Conference.  While there, Annie will be giving a talk on “Immunogenicity of Peptide Drugs and Their Impurities: Taspoglutide...
UPDATE: USP Workshop on Therapeutic Peptides and Oligonucleotides November 4th-5th, 2019

UPDATE: USP Workshop on Therapeutic Peptides and Oligonucleotides November 4th-5th, 2019

by Annie De Groot | Jun 28, 2019 | Events

UPDATE:  Review Dr. Anne De Groots presentation here Therapeutic Peptides and Oligonucleotides: Regulations, Standards and Quality USP Workshop Monday, November 4th – Tuesday, November 5th The U.S. Pharmacopoeia (USP) Therapeutic Peptides and Oligonucleotides:...
Breaking News: FDA awards $1 million to EpiVax, CUBRC, to assess generic peptide drugs

Breaking News: FDA awards $1 million to EpiVax, CUBRC, to assess generic peptide drugs

by Adam | Oct 5, 2018 | News

This original article was published on October 2nd, 2018 in ConvergenceRI. PROVIDENCE, RI – The U.S. Food and Drug Administration announced on Tuesday, Oct. 2, that the federal agency has awarded EpiVax and CUBRC a $1 million contract over two years to establish best...
Next Entries »

Recent Posts

  • The Amsterdam Immunogenicity & Tolerance Seminar: 2025
  • EpiVax Seminars in Tokyo
  • The Role of Treg Epitopes (Tregitopes) in Antibody Maturation Uncovered in New EpiVax Study: Implications for Therapeutic Antibodies
  • March of the Teenage B Cells
  • EpiVax Strengthens Technology Leadership Amid Immunoinformatics Advancements

Recent Comments

No comments to show.

Join our newsletter

 Stay up to date with EpiVax and greater industry news, events, and technological advancements with this monthly update written by EpiVax co-founder and CSO, Dr. Annie De Groot. 

Explore

Therapeutic In Silico Services

Vaccine In Silico Services

Lab Services

Consulting

LinkedIn

About Us

Careers

Partner

News

Events

Publications

Contact Us

We use cookies to ensure that we give you the best experience on our website. By clicking 'accept', you consent to our use of cookies.AcceptDecline